Literature DB >> 10096097

The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis.

J Iriarte1, G Katsamakis, P de Castro.   

Abstract

Although fatigue is common among multiple sclerosis (MS) patients, evaluation of this symptom is difficult due to the subjectivity and variability of the complaint. We proposed the Fatigue Descriptive Scale (FDS) as a tool to evaluate the severity and quality of fatigue in a group of patients suffering from MS. As a way to demonstrate the usefulness of this scale we applied the FDS in a group of 155 patients (105 women and 50 men) with clinically-definite multiple sclerosis, as outlined according to Poser's criteria. Age was 36.2 +/- 11.1 years (range 12-62) and time of evolution was 8.3 +/- 9.4 years (range 1-44). The Fatigue Severity Scale (FSS) was also used. Descriptive statistics techniques and techniques for nonparametric distribution (Spearman Rank, Kruskal-Wallis ANOVA) were used. One hundred and eighteen patients reported fatigue (73 spontaneously, 45 when questioned). All descriptions of fatigue were ranked according to FDS categories. Eighty-five patients defined the symptom as fatigue with exercise, 26 as asthenia and seven as the worsening of other symptoms. Fatigue by itself produced limited or disrupted activity in 78 patients; work-related functions were limited in 48 patients; social relations were limited in 29 patients; and self-care difficult for one patient. Fifty-six patients suffered fatigue daily. FDS score was 4.9 +/- 3.9 (range 0-13). FSS was 3.1 +/- 1.7 (range 0.2-6.6). FDS and FSS of Krupp were highly correlated (R = 0.87, p < 0.001). Therefore, in comparison with other scales, the FDS shows remarkable usefulness in classifying, periodicity, and severity of fatigue in MS patients. The high correlation with the FSS implies that it is a valid method to measure the severity of fatigue, as was demonstrated in our paper proposing the FDS. The importance of this new scale is its ability to inform the clinicians in a very quick, easy, and at the same time complete way, how severe the fatigue really is and how it affects the patient.

Entities:  

Mesh:

Year:  1999        PMID: 10096097     DOI: 10.1177/135245859900500103

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  20 in total

Review 1.  Fatigue in multiple sclerosis: definition, pathophysiology and treatment.

Authors:  Lauren B Krupp
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Carnitine for fatigue in multiple sclerosis.

Authors:  Aaron M Tejani; Michael Wasdell; Rae Spiwak; Greg Rowell; Shabita Nathwani
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  [Cognitive dysfunctions in multiple sclerosis patients].

Authors:  C Engel; B Greim; U K Zettl
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

4.  Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for Daily Use (D-FIS).

Authors:  Pablo Martinez-Martin; Maria Jose Catalan; Julian Benito-Leon; Angel Ortega Moreno; Ivana Zamarbide; Esther Cubo; Nadeje van Blercon; Victor Campos Arillo; Margarita Pondal; Gurutz Linazasoro; Fernando Alonso; Pedro García Ruiz; Belen Frades
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

5.  Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients.

Authors:  Hrayr Attarian; Garrick Applebee; Angela Applebee; Bingxia Wang; Melissa Clark; Becky McCormick; Emma Salzman; Catherine Schuman
Journal:  Int J MS Care       Date:  2011

6.  Demographic correlates of fatigue in the US general population: results from the patient-reported outcomes measurement information system (PROMIS) initiative.

Authors:  Doerte U Junghaenel; Christopher Christodoulou; Jin-Shei Lai; Arthur A Stone
Journal:  J Psychosom Res       Date:  2011-07-18       Impact factor: 3.006

Review 7.  Fatigue in multiple sclerosis.

Authors:  L B Krupp; C Christodoulou
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

8.  Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.

Authors:  Yvonne Benešová; Aleš Tvaroh
Journal:  Ther Adv Neurol Disord       Date:  2016-10-21       Impact factor: 6.570

Review 9.  Management of fatigue in patients with multiple sclerosis.

Authors:  Udo A Zifko
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Aiming for a better understanding and management of cancer-related fatigue.

Authors:  Elisabeth C W Neefjes; Maurice J D L van der Vorst; Susanne Blauwhoff-Buskermolen; Henk M W Verheul
Journal:  Oncologist       Date:  2013-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.